PT  - JOURNAL ARTICLE
AU  - Silk, Sarah E.
AU  - Kalinga, Wilmina F.
AU  - Mtaka, Ivanny M.
AU  - Lilolime, Nasoro S.
AU  - Mpina, Maximillian
AU  - Milando, Florence
AU  - Ahmed, Saumu
AU  - Diouf, Ababacar
AU  - Mkwepu, Fatuma
AU  - Simon, Beatus
AU  - Athumani, Thabit
AU  - Rashid, Mohammed
AU  - Mohammed, Latipha
AU  - Lweno, Omary
AU  - Ali, Ali M.
AU  - Nyaulingo, Gloria
AU  - Mwalimu, Bakari
AU  - Mswata, Sarah
AU  - Mwamlima, Tunu G.
AU  - Barrett, Jordan R.
AU  - Wang, Lawrence T.
AU  - Themistocleous, Yrene
AU  - King, Lloyd D. W.
AU  - Hodgson, Susanne H.
AU  - Payne, Ruth O.
AU  - Nielsen, Carolyn M.
AU  - Lawrie, Alison M.
AU  - Nugent, Fay L.
AU  - Cho, Jee-Sun
AU  - Long, Carole A.
AU  - Miura, Kazutoyo
AU  - Draper, Simon J.
AU  - Minassian, Angela M.
AU  - Olotu, Ally I.
TI  - Superior antibody immunogenicity of a RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
AID  - 10.1101/2023.04.17.23288686
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.17.23288686
4099  - http://medrxiv.org/content/early/2023/04/20/2023.04.17.23288686.short
4100  - http://medrxiv.org/content/early/2023/04/20/2023.04.17.23288686.full
AB  - Background RH5 is the leading blood-stage candidate antigen for inclusion in a Plasmodium falciparum malaria vaccine, however, its safety profile and ability to induce functional immune responses in a malaria-endemic population are unknown. Characterising safety and immunogenicity is key to refine and progress next-generation RH5-based blood-stage malaria vaccines to field efficacy assessment.Methods A Phase 1b, single-center, dose-escalation, age de-escalation, double-blind, randomized, controlled trial was conducted in Bagamoyo, Tanzania. Healthy adults (18-35 years), young children (1-6 years) and infants (6-11 months) were recruited to receive a priming dose of viral-vectored ChAd63 RH5 (or rabies control vaccine) followed by a booster dose of MVA RH5 (or rabies control vaccine) 8 weeks later. The primary outcomes were the number of solicited and unsolicited adverse events following vaccination and the number of serious adverse events over the whole study period. Secondary outcomes included quantitative and qualitative measures of the anti-RH5 immune response. All participants receiving at least one dose of vaccine were included in the primary analyses.Findings Between 12th April and 25th October 2018 a total of 63 adults, children and infants were recruited and primed and 60 of these were boosted, all completing six months of follow-up post-priming vaccination. Vaccinations were well-tolerated with participants reporting predominantly mild reactogenicity, with profiles comparable between ChAd63 RH5, MVA RH5 and rabies vaccine groups, and across the age groups. No serious adverse events were reported during the study period. RH5-specific T cell, B cell and serum antibody responses were induced by vaccination. Higher anti-RH5 serum IgG responses were observed post-boost in the 1-6 year old children (median 93 µg/mL; range: 31-508 µg/mL) and infants (median 149 µg/mL; range: 29-352 µg/mL) as compared to adults (median 14 µg/mL; range: 9-15 µg/mL). These contracted over time post-boost, but the same hierarchy of responses across the age groups was maintained to end of follow-up at 16 weeks post-boost (day 168). Vaccine-induced anti-RH5 antibodies were functional showing growth inhibition activity (GIA) in vitro against P. falciparum blood-stage parasites. The highest levels were observed in the 6-11 month old infants, with 6/11 showing >60% GIA following dilution of total IgG to 2.5 mg/mL (median 61%; range: 41-78%).Interpretation The ChAd63-MVA RH5 vaccine regimen shows an acceptable safety and reactogenicity profile and encouraging immunogenicity in children and infants residing in a malaria-endemic area. The levels of functional GIA observed in the RH5 vaccinated 6-11 month old infants are the highest levels reported to-date following human vaccination. These data support onward clinical development of RH5-based blood-stage vaccines that aim to protect against clinical malaria in young African infants.Funding Medical Research Council, London, United Kingdom.Trial Registration ISRCTN registry: 47448832 and ClinicalTrials.gov: NCT03435874.Competing Interest StatementSJD is a named inventor on patent applications relating to RH5 malaria vaccines and adenovirus-based vaccines, is an inventor on intellectual property licensed by Oxford University Innovation to AstraZeneca, and has been a consultant to GSK on malaria vaccines. AMM has been a consultant to GSK on malaria vaccines, and has an immediate family member who is an inventor on patent applications relating to RH5 malaria vaccines and adenovirus-based vaccines, and is an inventor on intellectual property licensed by Oxford University Innovation to AstraZeneca. All other authors have declared that no conflict of interest exists.Clinical TrialNCT03435874Funding StatementThis work was funded in part by an African Research Leader Award to AIO from the UK Medical Research Council (MRC) [MR/P020593/1]. This award was jointly funded by the UK MRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. This work was also supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The GIA work was supported by the United States Agency for International Development (USAID) and the Intramural Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. SHH holds an NIHR Academic Clinical Lectureship. CMN held a Sir Henry Wellcome Postdoctoral Fellowship [209200/Z/17/Z]. SJD is a Jenner Investigator and held a Wellcome Trust Senior Fellowship [106917/Z/15/Z].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The VAC070 clinical trial was approved by the Oxford Tropical Research Ethics Committee in the UK (OxTREC, reference 29-17); the Ifakara Health Institute Institutional Review Board in Tanzania (reference: 20-2017); the National Institute for Medical Research in Tanzania, the National Health Research Ethics Sub-Committee (NatHREC) and the then Tanzania Food and Drugs Authority (now the Tanzania Medicines and Medical Devices Authority), reference: TFDA0017/CTR/0015/3.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors